Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.

about

Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life Gd-EOB-DTPA DCE-MRI biomarkers in a rabbit model of liver fibrosis

P2860

Q57296265-7B136E35-BB92-4925-8E5D-D66AD37457FA Q57493366-2E2F651A-AB58-4F14-AC2D-DB4A437A2DC5

P2860

Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.

Item

http://www.wikidata.org/entity/Q41921724

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Baseline NS5A Resistance Assoc ...... al-World Hepatitis C Patients.

@en

type

Item

label

Baseline NS5A Resistance Assoc ...... al-World Hepatitis C Patients.

@en

prefLabel

Baseline NS5A Resistance Assoc ...... al-World Hepatitis C Patients.

@en

P1476

Baseline NS5A resistance assoc ...... eal-world hepatitis C patients

@en

P2093

Ana Arias

http://www.w3.org/2001/XMLSchema#string

Gemma Lledó

http://www.w3.org/2001/XMLSchema#string

Itzíar Carrasco

http://www.w3.org/2001/XMLSchema#string

Laura Benítez-Gutiérrez

http://www.w3.org/2001/XMLSchema#string

Miriam Cuesta

http://www.w3.org/2001/XMLSchema#string

Silvia Requena

http://www.w3.org/2001/XMLSchema#string

P2860

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.

Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.

Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.

P304

532-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.24971

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Valentín Cuervas-Mons

Carmen de Mendoza

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28990680

http://www.w3.org/2001/XMLSchema#string

Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.

about

P2860

P2860

Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698